JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ji, S.
Right arrow Articles by Ebert, S. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ji, S.
Right arrow Articles by Ebert, S. N.

Vol. 301, Issue 3, 893-899, June 2002

Differential Rate Responses to Nicotine in Rat Heart: Evidence for Two Classes of Nicotinic Receptors

Susan Ji, Toshimasa Tosaka, Bernard H. Whitfield, Alexander N. Katchman, Abdurrahman Kandil, Bjoern C. Knollmann and Steven N. Ebert

Department of Pharmacology, Georgetown University Medical Center, Washington, DC

Nicotinic acetylcholine receptors are pentameric, typically being composed of two or more different subunits. To investigate which receptor subtypes are active in the heart, we initiated a series of experiments using an isolated perfused rat heart (Langendorff) preparation. Nicotine administration (100 µM) caused a brief decrease (-7 ± 2%) followed by a much larger increase (17 ± 5%) in heart rate that slowly returned to baseline within 10 to 15 min. The nicotine-induced decrease in heart rate could be abolished by an alpha 7-specific antagonist, alpha -bungarotoxin (100 nM). In contrast, the nicotine-induced increase in heart rate persisted in the presence of alpha -bungarotoxin. These results suggest that the nicotinic acetylcholine receptors (nAChRs) that mediate the initial decrease in heart rate probably contain alpha 7 subunits, whereas those that mediate the increase in heart rate probably do not contain alpha 7 subunits. To investigate which subunits may contribute to the nicotine-induced increase in heart rate, we repeated our experiments with cytisine, an agonist at nAChRs that contain beta 4 subunits. The cytisine results were similar to those obtained with nicotine, thereby suggesting that the nAChRs on sympathetic nerve terminals in the heart probably contain beta 4 subunits. Thus, the results of this study show that pharmacologically distinct nAChRs are responsible for the differential effects of nicotine on heart rate. More specifically, our results suggest that alpha 7 subunits participate in the initial nicotine-induced heart rate decrease, whereas beta 4 subunits help to mediate the subsequent nicotine-induced rise in heart rate.


0022-3565/02/3013-0893$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
E. G. Severance, H. Zhang, Y. Cruz, S. Pakhlevaniants, S. H. Hadley, J. Amin, L. Wecker, C. Reed, and J. Cuevas
The {alpha}7 Nicotinic Acetylcholine Receptor Subunit Exists in Two Isoforms that Contribute to Functional Ligand-Gated Ion Channels
Mol. Pharmacol., September 1, 2004; 66(3): 420 - 429.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Tosaka, M. C. Casimiro, Q. Rong, S. Tella, M. Oh, A. N. Katchman, J. C. Pezzullo, K. Pfeifer, and S. N. Ebert
Nicotine Induces a Long QT Phenotype in Kcnq1-Deficient Mouse Hearts
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 980 - 987.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.